Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours.

A tumour-associated trypsin inhibitor (TATI) and the cancer antigen 125 (CA 125) were measured pre- or peroperatively in 30 patients with mucinous ovarian tumours (10 malignant, two borderline and 18 benign) to investigate the separate and combined use of the two markers as a diagnostic tool. In the...

Descripción completa

Detalles Bibliográficos
Autores principales: Mogensen, O., Mogensen, B., Jakobsen, A.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1990
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971406/
https://www.ncbi.nlm.nih.gov/pubmed/2310684
_version_ 1782134903487332352
author Mogensen, O.
Mogensen, B.
Jakobsen, A.
author_facet Mogensen, O.
Mogensen, B.
Jakobsen, A.
author_sort Mogensen, O.
collection PubMed
description A tumour-associated trypsin inhibitor (TATI) and the cancer antigen 125 (CA 125) were measured pre- or peroperatively in 30 patients with mucinous ovarian tumours (10 malignant, two borderline and 18 benign) to investigate the separate and combined use of the two markers as a diagnostic tool. In the malignant and borderline cases considered as a whole, TATI was elevated in 83% and CA 125 in 50%. The former marker was increased in one (6%) benign tumour and the latter in another (6%). The combined use of TATI and CA 125 ensured diagnosis of all malignant and borderline tumours. The specificity was 89% and the positive predictive value 86%. In conclusion, in the distinction of malignant and borderline mucinous ovarian tumours from benign ones TATI was a more reliable tumour marker than CA 125. The combined use of TATI and CA 125 ensured diagnosis of all malignant and borderline tumours in the present series.
format Text
id pubmed-1971406
institution National Center for Biotechnology Information
language English
publishDate 1990
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19714062009-09-10 Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours. Mogensen, O. Mogensen, B. Jakobsen, A. Br J Cancer Research Article A tumour-associated trypsin inhibitor (TATI) and the cancer antigen 125 (CA 125) were measured pre- or peroperatively in 30 patients with mucinous ovarian tumours (10 malignant, two borderline and 18 benign) to investigate the separate and combined use of the two markers as a diagnostic tool. In the malignant and borderline cases considered as a whole, TATI was elevated in 83% and CA 125 in 50%. The former marker was increased in one (6%) benign tumour and the latter in another (6%). The combined use of TATI and CA 125 ensured diagnosis of all malignant and borderline tumours. The specificity was 89% and the positive predictive value 86%. In conclusion, in the distinction of malignant and borderline mucinous ovarian tumours from benign ones TATI was a more reliable tumour marker than CA 125. The combined use of TATI and CA 125 ensured diagnosis of all malignant and borderline tumours in the present series. Nature Publishing Group 1990-02 /pmc/articles/PMC1971406/ /pubmed/2310684 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Mogensen, O.
Mogensen, B.
Jakobsen, A.
Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours.
title Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours.
title_full Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours.
title_fullStr Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours.
title_full_unstemmed Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours.
title_short Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours.
title_sort tumour-associated trypsin inhibitor (tati) and cancer antigen 125 (ca 125) in mucinous ovarian tumours.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971406/
https://www.ncbi.nlm.nih.gov/pubmed/2310684
work_keys_str_mv AT mogenseno tumourassociatedtrypsininhibitortatiandcancerantigen125ca125inmucinousovariantumours
AT mogensenb tumourassociatedtrypsininhibitortatiandcancerantigen125ca125inmucinousovariantumours
AT jakobsena tumourassociatedtrypsininhibitortatiandcancerantigen125ca125inmucinousovariantumours

Ejemplares similares